Icon

TABRECTA (nda213591)- (EQ 150MG BASE,EQ 200MG BASE)

CAPMATINIB HYDROCHLORIDE NOVARTIS PHARM
EQ 150MG BASE,EQ 200MG BASE
Yes No
2035-Jul-22 2025-May-06
None None
None No
TABRECTA is a kinase inhibitor indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping as detected by an FDA-approved test.
0 0 0
Total Other Developers 2
Drugs with Suitability No
EQ 150MG BASE ** ** - - -
EQ 200MG BASE ** ** - - -
NDA Sales Available Total Generic Sales Available
Yes 0
ANDA No Generic Co Manufacturer Name Operations Manufacturer Address Country

Download GenUS Drug Report


Download GenUS Detailed Report


To get detailed report Contact Us

GenUs Advanced Search




Expired
to
Expired
to


Brand Name Generic Name Strength Dosage Route of Administration Innovator ParaIV

Please contact contact@researchdelta.com to get more details.